(1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid

• ChemBase编号: 154138
• 分子式: C14H15Cl2NO3
• 平均质量: 316.1798
• 单一同位素质量: 315.04289871
• SMILES: c1c(cc(cc1Cl)Cl)NC(=O)[C@H]1CCCC[C@H]1C(=O)O
• Canonical SMILES: O=C([C@H]1CCCC[C@H]1C(=O)O)Nc1cc(Cl)cc(c1)Cl
• InChI: InChI=1S/C14H15Cl2NO3/c15-8-5-9(16)7-10(6-8)17-13(18)11-3-1-2-4-12(11)14(19)20/h5-7,11-12H,1-4H2,(H,17,18)(H,19,20)/t11-,12+/m0/s1
• InChIKey: VSMUYYFJVFSVCA-NWDGAFQWSA-N

名称和登记号

名称

• IUPAC标准名: (1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
• IUPAC传统名: (1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
• 别名: (±)-cis-2-(3,5-Dicholorphenylcarbamoyl)cyclohexanecarboxylic acid; VU0155041

登记号

• MDL号: MFCD03544581
• PubChem SID: 162248277
• PubChem CID: 888023

理论计算性质

• Acid pKa: 3.913924
• 质子受体: 3
• 质子供体: 2
• LogD (pH = 5.5): 2.1630151
• LogD (pH = 7.4): 0.54895
• Log P: 3.7552922
• 摩尔折射率: 77.9727 cm^3
• 极化性: 29.89485 Å^3
• 极化表面积: 66.4 Å^2
• 可自由旋转的化学键: 3
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: DMSO: soluble54 mg/mL
• 外观: white powder

安全信息

• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 3
• 危险公开号: 22
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H302
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves

产品相关信息

• 纯度: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C14H15Cl2NO3

详细说明

Sigma Aldrich - V1640

Biochem/physiol Actions
VU0155041 is a mixed allosteric agonist/positive allosteric modulator (PAM) of mGluR4. VU0155041 is approximately 8-fold more potent than PHCCC and does not show any significant potentiator or antagonist activity at other mGluR subtypes. It is soluble in an aqueous vehicle and intracerebroventricular administration of 31-316 nmol of VU0155041 dose-dependently decreased haloperidol-induced catalepsy and reserpine-induced akinesia in rats. VU0155041 exhibits selectivity for mGluR4 relative to 67 different targets and does not affect the function of striatal NMDA receptors.
VU0155041 is a positive allosteric modulator of the metabotropic glutamate receptor subtype 4. It also shows some direct agonist activity, but at a site different from the glutamate binding site. /VU0155041 is approximately 8-fold more potent than PHCCC and enhances the activity of glutamate also about 8-fold. It shows promising anti-Parkinsonian effects in animal models of Parkinson′s disease.